Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Astria Stockholders Vote to Approve Acquisition by BioCryst
Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their Rights
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights